Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

Journal of Neurology

Volumn 262, Issue 10, 2015, Pages 2329-2335

  Zéphir, Hélène ^a   Bernard Valnet, Raphaël ^b   Lebrun, Christine ^c   Outteryck, Olivier ^a   Audoin, Bertrand ^d   Bourre, Bertrand ^e   Pittion, Sophie ^f   Wiertlewski, Sandrine ^g   Ouallet, Jean Christophe ^h   Neau, Jean Philippe ⁱ   Ciron, Jonathan ⁱ   Clavelou, Pierre ^j   Marignier, Romain ^k   Brassat, David ^b  

^a UNIV LILLE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c PASTEUR HOSPITAL   (France)

^d TIMONE HOSPITAL   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^k HÔPITAL NEUROLOGIQUE   (France)

more..

Author keywords

Aquaporin 4; B Cell depletion; Immunosuppression; Neuromyelitis optica; Relapse free; Rituximab

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; FOLLOW UP; MIDDLE AGED; NEUROMYELITIS OPTICA; OUTCOME ASSESSMENT; RECURRENT DISEASE;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RITUXIMAB;

EID: 84944515127     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7852-y     Document Type: Article

References (19)

1. Kimbrough DJ, Fujihara K, Jacob A et al (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1:180–187
2. Jacob A, Matiello M, Weinshenker BG et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128–1133
3. Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659–666
4. Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443–1448
5. Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310–1315
6. Cabre P, Olindo S, Marignier R et al (2013) Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 84:511–516
7. Kim SH, Kim W, Li XF et al (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68:1412–1420
8. Kim SH, Huh SY, Lee SJ et al (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110–1117
9. Yang CS, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81:710–713
10. Ip VH, Lau AY, Au LW et al (2013) Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 324:38–39
11. Mealy MA, Wingerchuk DM, Palace J et al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324–330
12. Araki M, Matsuoka T, Miyamoto K et al (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82:1302–1306
13. Krumbholz M, Meinl E (2014) B Cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol 36(3):339–350
14. Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489
15. Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, [Epub ahead of print]
16. Marignier R, Vukusic S, Collongues N, Zephir H, Papeix C, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Stankoff B, De Seze J, Confavreux C, for the NOMADMUS study group and the Observatoire Français de la Sclérose En Plaques (OFSEP) (2013) Mycophenolate Mofetil as first line therapy in neuromyelitis optica spectrum disorder: retrospective multicenter study on 64 cases. Mult Scler 2013 19(Suppl 11):91–92
17. Kim SM, Park J, Kim SH et al (2013) Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One 16:e82325
18. van Vollenhoven RF, Emery P, Bingham CO 3rd et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496–1502
19. Dass S, Rawstron AC, Vital EM et al (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58:2993–2999